BASEL, Switzerland,
February 8, 2017 /PRNewswire/ --
Dr. Reddy's Laboratories Ltd announced today the expansion
of its commercial operations in Europe with the introduction of its portfolio
of generics in France. The
first products will be made available in the hospital market
in March 2017 in the area of oncology
and anti-infectives, including antimycotics.
The company recently launched select products of its hospital
portfolio in Italy and
Spain, and is looking to further
strengthen its presence in the two countries with the launch of
anti-HIV products this year.
Abhijit Mukherjee, Chief
Operating Officer, Dr. Reddy's Laboratories said, "It is our
constant endeavor to enhance the reach of our affordable and
difficult-to-produce drugs. Our business expansion in Europe is a testimony to Dr. Reddy's
commitment to ensure access to affordable medicine for patients
across the globe."
With a diversified portfolio of injectables and complex
generics, Dr. Reddy's currently has two R&D centres, one
manufacturing, and a packaging and storage facility in Europe.
About Dr. Reddy's: Dr. Reddy's Laboratories Ltd. (BSE:
500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical
company, committed to providing affordable and innovative medicines
for healthier lives. Through its three businesses - Pharmaceutical
Services & Active Ingredients, Global Generics and Proprietary
Products - Dr. Reddy's offers a portfolio of products and services
including APIs, custom pharmaceutical services, generics,
biosimilars and differentiated formulations. Our major therapeutic
areas of focus are gastrointestinal, cardiovascular, diabetology,
oncology, pain management and dermatology. Dr. Reddy's operates in
markets across the globe. Our major markets include - USA, India,
Russia & CIS countries, and
Europe. For more information, log
on to: http://www.drreddys.com
Disclaimer: This press release may include statements of
future expectations and other forward-looking statements that are
based on the management's current views and assumptions and involve
known or unknown risks and uncertainties that could cause actual
results, performance or events to differ materially from those
expressed or implied in such statements. In addition to statements
which are forward-looking by reason of context, the words "may",
"will", "should", "expects", "plans", "intends", "anticipates",
"believes", "estimates", "predicts", "potential", or "continue" and
similar expressions identify forward-looking statements. Actual
results, performance or events may differ materially from those in
such statements due to without limitation, (i) general
economic conditions such as performance of financial markets,
credit defaults , currency exchange rates , interest rates ,
persistency levels and frequency / severity of insured loss events
(ii) mortality and morbidity levels and trends, (iii) changing
levels of competition and general competitive factors, (iv) changes
in laws and regulations and in the policies of central banks and/or
governments, (v) the impact of acquisitions or reorganization ,
including related integration issues.
The company assumes no obligation to update any information
contained herein.
CONTACT
Investor relations
Saunak SAVLA
saunaks@drreddys.com
(Ph: +91-40-49002135)
Media relations
Calvin Printer
calvinprinter@drreddys.com
(Ph: +91-40-49002121)